

KING PHARMACEUTICALS INC

Form 8-K

January 09, 2003

**Table of Contents**

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 8, 2003

**King Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

**Tennessee**  
(State or other jurisdiction  
of incorporation)

**0 24425**  
(Commission  
File Number)

**54-1684963**  
(IRS Employer  
Identification Number)

**501 Fifth Street, Bristol, Tennessee**  
(Address of principal executive offices)

**37620**  
(Zip Code)

Registrant's telephone number, including area code: **423-989-8000**

Not Applicable  
(Former name or former address, if changed since last report)

---

---

**TABLE OF CONTENTS**

SIGNATURE

Exhibit Index

PRESS RELEASE

PRESS RELEASE

---

**Table of Contents**

**Item 5. Other Events**

Effective January 8, 2003, King Pharmaceuticals, Inc., a Tennessee corporation, merged with Meridian Medical Technologies, Inc. The transaction was previously announced. Under the terms of the agreement, Meridian shareholders will receive a cash payment of \$44.50 for each share of Meridian common stock held of record on January 8, 2003. On January 8 and January 9, 2003, King issued press releases regarding, respectively, the approval of the transaction by shareholders of Meridian and the closing of the transaction.

**Item 7. Financial Statements, Pro Forma Financial Information and Exhibits**

(a) Financial Statements on Businesses Acquired.

None.

(b) Pro Forma Financial Information.

None.

(c) Exhibits.

The following exhibits are filed pursuant to Item 601 of Regulation S-K:

**Exhibits:**

<b>Exhibit Number</b>	<b>Description of Exhibit</b>
99.1	Press Release of King Pharmaceuticals, Inc. dated January 8, 2003.
99.2	Press Release of King Pharmaceuticals, Inc. dated January 9, 2003.

---

**Table of Contents**

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 9, 2003

KING PHARMACEUTICALS, INC.

By: /s/ James R. Lattanzi  
James R. Lattanzi  
Chief Financial Officer

---

**Table of Contents**

**Exhibit Index**

<b>Exhibit Number</b>	<b>Description of Exhibit</b>
99.1	Press Release of King Pharmaceuticals, Inc. dated January 8, 2003.
99.2	Press Release of King Pharmaceuticals, Inc. dated January 9, 2003.